Pediatrix Medical Group (NYSE:MD) Shares Gap Up – Should You Buy?

Pediatrix Medical Group, Inc. (NYSE:MD)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $12.44, but opened at $13.18. Pediatrix Medical Group shares last traded at $12.98, with a volume of 35,468 shares trading hands.

Wall Street Analyst Weigh In

MD has been the subject of a number of analyst reports. Macquarie assumed coverage on Pediatrix Medical Group in a report on Monday, December 16th. They issued an “outperform” rating and a $18.00 price target for the company. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Jefferies Financial Group lifted their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. UBS Group upped their price objective on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, StockNews.com upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $16.25.

Pediatrix Medical Group Stock Up 3.8 %

The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -4.22, a price-to-earnings-growth ratio of 2.00 and a beta of 1.58. The firm’s 50-day moving average is $14.30 and its 200 day moving average is $11.62.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. During the same period in the prior year, the firm posted $0.29 EPS. The business’s revenue for the quarter was up .9% on a year-over-year basis. Sell-side analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

A number of hedge funds have recently made changes to their positions in the company. Rubric Capital Management LP grew its stake in Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after purchasing an additional 7,241,400 shares in the last quarter. Dana Investment Advisors Inc. boosted its stake in shares of Pediatrix Medical Group by 80.3% during the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after buying an additional 455,785 shares during the last quarter. Weiss Asset Management LP grew its position in shares of Pediatrix Medical Group by 50.5% during the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after buying an additional 306,143 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Pediatrix Medical Group by 639.4% in the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock worth $2,192,000 after buying an additional 251,072 shares during the last quarter. Finally, RBF Capital LLC bought a new stake in shares of Pediatrix Medical Group in the third quarter worth $1,695,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.